Amoebiasis (Amoebic Dysentery)

1. Clinical Overview

Summary

Amoebiasis is a parasitic infection caused by the protozoan Entamoeba histolytica, transmitted via the faecal-oral route through ingestion of cysts in contaminated food or water. The infection spectrum ranges from asymptomatic cyst carriage (most common) to invasive intestinal disease (amoebic colitis with bloody diarrhoea) and extraintestinal dissemination, most notably amoebic liver abscess (ALA). [1,2]

E. histolytica is responsible for approximately 40,000-100,000 deaths annually worldwide, making it the third leading cause of death from parasitic diseases after malaria and schistosomiasis. [3] The parasite is endemic in tropical and subtropical regions with poor sanitation, particularly Central and South America, Africa, and South Asia. [4]

A critical diagnostic distinction exists between E. histolytica (pathogenic) and the morphologically identical but non-pathogenic E. dispar, which accounts for approximately 90% of infections previously identified as amoebiasis. [5] Molecular techniques (PCR, antigen detection) are required to differentiate these species.

Treatment mandates dual therapy: a tissue amoebicide (metronidazole or tinidazole) to eradicate invasive trophozoites, followed by a luminal amoebicide (paromomycin or diloxanide furoate) to eliminate intestinal cysts and prevent relapse or ongoing transmission. [6]

Key Facts

• Global burden: 500 million people infected with Entamoeba species; ~10% are E. histolytica (pathogenic)
• Symptomatic disease: 50 million cases of invasive amoebiasis annually
• Mortality: 40,000-100,000 deaths per year (third deadliest parasitic disease)
• Asymptomatic carriage: 90% of E. histolytica infections remain asymptomatic
• Invasive disease risk: 10% of E. histolytica infections progress to symptomatic disease
• ALA demographics: 80% occur in young adult males aged 20-40 years
• ALA location: Right hepatic lobe affected in 75-80% of cases
• Diagnosis: Erythrophagocytosis (trophozoites with ingested RBCs) is pathognomonic
• Serology sensitivity: 95% positive in ALA, 70% in amoebic colitis
• Treatment essentials: BOTH tissue amoebicide AND luminal amoebicide required
• ALA cure rate: 90-95% with medical therapy alone
• Mortality (untreated ALA): 10-30% if ruptured; less than 1% if treated appropriately

Clinical Pearls

Erythrophagocytosis Defines Pathogenicity: The presence of trophozoites containing ingested red blood cells (erythrophagocytosis) is pathognomonic for E. histolytica and definitively distinguishes it from non-pathogenic E. dispar. This finding on fresh stool microscopy confirms invasive amoebiasis. [5]

"Anchovy Sauce" Pus: Aspirate from amoebic liver abscess classically has a reddish-brown "anchovy paste" or "chocolate sauce" appearance due to lysed hepatocytes and blood. Critically, it is sterile on bacterial culture (distinguishing it from pyogenic abscess) and trophozoites are rarely visualized in the aspirate itself (they reside in the abscess wall). [7]

Two Drugs, Two Jobs — Both Mandatory: Metronidazole kills invasive trophozoites in tissues but does NOT eradicate cysts in the intestinal lumen. Failure to follow with a luminal agent (paromomycin or diloxanide) results in 40-60% recurrence rates and continued cyst shedding, perpetuating transmission. This is a common treatment error. [6]

Male Predominance in ALA: Amoebic liver abscess occurs 7-10 times more frequently in men than women, despite equal intestinal infection rates. The mechanism is poorly understood but may involve testosterone-mediated immune modulation or differences in hepatic immune responses. [8]

Left Lobe = Higher Risk: Left lobe liver abscesses, though less common (20% vs. 80% right lobe), carry higher mortality due to risk of rupture into the pericardium, causing fatal cardiac tamponade. These require more aggressive management including earlier drainage. [9]

Diarrhoea Often Absent in ALA: Only 20-30% of patients with amoebic liver abscess present with concurrent diarrhoea. The interval from intestinal infection to ALA development can be weeks to months, by which time bowel symptoms have often resolved. [10]

Why This Matters Clinically

Amoebiasis is a critical diagnosis in returning travellers and immigrants from endemic regions, yet it is frequently missed or misdiagnosed as bacterial dysentery or inflammatory bowel disease. [11] Key clinical implications include:

1. Diagnostic stewardship: Distinguishing E. histolytica from E. dispar prevents unnecessary treatment of non-pathogenic colonization
2. Treatment completion: Inadequate treatment (tissue agent alone) leads to relapse and ongoing transmission
3. ALA recognition: Liver abscess can develop weeks to months after travel, requiring high index of suspicion
4. Public health: Asymptomatic cyst carriers are the primary reservoir for transmission
5. Mortality prevention: Early diagnosis and treatment of ALA reduces mortality from 10-30% (if ruptured) to less than 1%

---

2. Epidemiology

Global Burden

Amoebiasis represents a significant global health burden, disproportionately affecting resource-limited settings with inadequate sanitation and water treatment infrastructure. [3,4]

Infection Prevalence:

• Overall infections: 500 million people infected with Entamoeba species (histolytica + dispar)
• E. histolytica (pathogenic): Approximately 50 million people (10% of total)
• E. dispar (non-pathogenic): Approximately 450 million people (90% of total)
• Symptomatic disease: 50 million cases of invasive amoebiasis per year
• Mortality: 40,000-100,000 deaths annually (third leading parasitic cause of death after malaria and schistosomiasis) [3]

Geographic Distribution:

The highest burden regions include: [4]

Industrialized Nations:

• Prevalence: less than 1%
• Cases primarily among: Travellers returning from endemic areas, recent immigrants, men who have sex with men (MSM), institutionalized populations [12]

Incidence & Prevalence

Intestinal Amoebiasis:

• Asymptomatic carriage: 90% of E. histolytica infections
• Symptomatic colitis: 10% of infections progress to invasive disease
• Annual incidence (endemic areas): 2-5 cases per 1,000 population
• Traveller incidence: 1-3% of travellers to highly endemic regions

Amoebic Liver Abscess (ALA):

• Global incidence: 3-9 cases per 100,000 in endemic areas
• Male:female ratio: 7-10:1 [8]
• Peak age: 20-40 years (75% of cases)
• Bilateral/multiple abscesses: 10-15% of ALA cases
• Concurrent intestinal symptoms: Only 20-30% have diarrhoea [10]

Time Course:

• Incubation period: 2-4 weeks (range: days to years)
• ALA development: Can occur 2-5 months (or longer) after intestinal infection
• Chronic carriage: Asymptomatic cyst excretion can persist for years without treatment

Demographics

Age Distribution:

• Intestinal amoebiasis: All ages affected; children and adults equally susceptible
• ALA: Peak incidence 20-40 years (75% of cases); uncommon in children (less than 10% of ALA)
• Severe complications: Higher rates in extremes of age (less than 5 years, >60 years)

Sex Differences:

• Intestinal infection: Equal male:female ratio
• Amoebic liver abscess: Male predominance 7-10:1 [8]
• Mechanism: Unclear; hypotheses include testosterone-mediated immune effects, alcohol consumption patterns, occupational exposures

Special Populations at Risk:

Risk Factors

Environmental:

• Poor sanitation: Lack of sewage treatment and safe water supply
• Contaminated water sources: Wells, rivers, untreated municipal water
• Contaminated food: Raw vegetables, fruits, food handlers with poor hygiene
• Overcrowding: Refugee camps, slums, institutions
• Tropical/subtropical climate: Warmer temperatures favor cyst survival

Host Factors:

• Immunosuppression: HIV/AIDS, corticosteroid therapy, chemotherapy, organ transplantation
• Malnutrition: Protein-energy malnutrition, micronutrient deficiencies
• Alcohol consumption: Increases ALA risk (hepatic susceptibility)
• Male sex: 7-10× increased ALA risk [8]
• Genetic susceptibility: HLA-DR3, lectin receptor polymorphisms
• Achlorhydria: Reduced gastric acid (PPI use, gastric surgery) permits cyst survival

Behavioral:

• Travel to endemic regions: Highest risk in South Asia, Central America, Africa
• Oral-anal sexual practices: MSM population at higher risk [12]
• Poor hand hygiene: Primary transmission route
• Consumption of raw foods: Uncooked vegetables, salads in endemic areas

---

3. Pathophysiology

Organism Characteristics

Entamoeba histolytica is a protozoan parasite with two main life cycle stages: [1,2]

1. Cyst (infective form):

   • Size: 10-15 μm diameter
   • Contains 4 nuclei when mature
   • Resistant to gastric acid, chlorination, and environmental stresses
   • Survives weeks to months in moist environments
   • Transmitted via faecal-oral route

2. Trophozoite (pathogenic form):

   • Size: 10-60 μm (larger when invasive)
   • Single nucleus with central karyosome
   • Motile (pseudopodia)
   • Ingests red blood cells (erythrophagocytosis) — pathognomonic feature [5]
   • Dies rapidly outside host; not infectious
   • Responsible for tissue invasion and damage

Life Cycle and Transmission

Step 1: Transmission

• Mature quadrinucleate cysts ingested via contaminated water or food
• Cyst dose as low as 10-100 cysts can cause infection
• Cysts resistant to gastric acid; pass through stomach intact

Step 2: Excystation

• Occurs in terminal ileum/proximal colon (alkaline pH, reduced oxygen)
• Each cyst undergoes nuclear division and cytoplasmic division
• Produces 8 small trophozoites (metacystic trophozoites)

Step 3: Colonization

• Trophozoites colonize colonic mucosa, particularly cecum and ascending colon
• Adhere to mucus layer and epithelium via Gal/GalNAc lectin
• 90% remain asymptomatic — commensal colonization
• Trophozoites encyst in colonic lumen → fecal shedding → transmission continues

Step 4: Invasion (10% of infections)

• Trophozoites breach mucosal barrier and invade colonic epithelium
• Contact-dependent cytolysis kills host cells
• Creates characteristic "flask-shaped ulcers" (narrow neck, broad base)
• Causes amoebic colitis with bloody diarrhoea

Step 5: Extraintestinal Dissemination

• Trophozoites enter portal venous circulation
• Majority are filtered and destroyed in liver
• In susceptible hosts, trophozoites survive and establish hepatic infection
• Causes amoebic liver abscess (ALA) — most common extraintestinal manifestation
• Rare dissemination: lung, brain, pericardium, genitourinary tract

Molecular Mechanisms of Pathogenicity

E. histolytica employs multiple virulence factors to invade and destroy host tissues: [13,14]

1. Adhesion (Gal/GalNAc Lectin):

• Surface glycoprotein that binds galactose/N-acetylgalactosamine residues
• Mediates adherence to colonic mucus, epithelial cells, and extracellular matrix
• Contact is prerequisite for cytolysis
• Also binds to host neutrophils and complement components

2. Contact-Dependent Cytolysis:

• Amoebapores: Pore-forming peptides (similar to NK cell perforins) inserted into target cell membrane
• Create ion channels → osmotic lysis of host cells
• Activity increases with contact duration

3. Proteolytic Enzymes:

• Cysteine proteases (EhCP-A5, EhCP-A1): Degrade colonic mucus barrier, extracellular matrix (collagen, fibronectin, laminin)
• Enable deeper tissue penetration
• Cleave IgA, IgG, complement components → immune evasion
• Degrade antimicrobial peptides

4. Immune Evasion:

• Complement resistance: Binds C8 and C9, preventing membrane attack complex formation
• Neutrophil killing: Kills neutrophils via contact-dependent lysis before phagocytosis
• Antigen variation: Alters surface antigens to evade antibody responses
• Inhibition of apoptosis: Prevents host cell programmed death to prolong colonization

5. Phagocytosis:

• Amoeba ingests host cells, bacteria, and red blood cells (erythrophagocytosis)
• Provides nutrients and is marker of pathogenicity [5]

Intestinal Pathology

Macroscopic Features:

• Distribution: Cecum, ascending colon > rectosigmoid > entire colon
• Flask-shaped ulcers: Pathognomonic finding
  • Narrow opening at mucosal surface (2-3 mm)
  • Broad undermined base (up to 2 cm)
  • Mucosa between ulcers appears normal (unlike inflammatory bowel disease)
• Amoeboma: Granulomatous mass lesion mimicking colon cancer (rare, 1-2%)
• Fulminant colitis: Transmural necrosis, toxic megacolon (2-5% of cases)
• Perforation: Usually cecum or sigmoid (1% of cases)

Microscopic Features:

• Ulceration with undermining necrosis
• Trophozoites at ulcer edge and base (demonstrable with PAS stain)
• Minimal acute inflammatory infiltrate (in contrast to bacterial dysentery)
• Thrombosis of submucosal vessels
• Flask-shaped configuration extending to muscularis propria

Hepatic Pathology (Amoebic Liver Abscess)

Pathogenesis:

• Trophozoites reach liver via portal circulation from intestinal lesions
• Right hepatic lobe preferentially affected (75-80%) due to streaming pattern in portal vein [9]
• Local hepatocyte necrosis → abscess formation
• Abscess enlarges via progressive liquefactive necrosis

Macroscopic Features:

• Size: 2-20 cm (median 5-10 cm)
• Number: Solitary (85%), multiple (15%)
• Location: Right lobe > left lobe (4:1 ratio)
• Contents: "Anchovy paste" or "chocolate sauce" pus
  • Reddish-brown color from lysed hepatocytes and blood
  • Thick, odorless (unless secondary bacterial infection)
  • Sterile on bacterial culture [7]
• Wall: Fibrous capsule with trophozoites at periphery (not in pus itself)

Microscopic Features:

• Central necrosis with acellular debris
• Surrounding hepatocyte lysis
• Minimal acute inflammatory response (in contrast to pyogenic abscess)
• Trophozoites at advancing edge (not in necrotic center)
• No granuloma formation

Complications of ALA:

• Rupture into peritoneum (6-9%): Peritonitis, shock
• Rupture into pleural cavity (5-15%): Empyema, hepatobronchial fistula
• Rupture into pericardium (1-2%): Cardiac tamponade (high mortality, especially left lobe abscesses) [9]
• Secondary bacterial infection (5-10%): Pyogenic conversion
• Hepatic vein thrombosis: Budd-Chiari syndrome (rare)

Rare Extraintestinal Sites

• Pulmonary: Direct extension from liver, or hematogenous spread → lung abscess, empyema
• Cerebral: Brain abscess (mortality >70%) [15]
• Pericardial: Tamponade (mortality 40-60%)
• Cutaneous: Perianal, abdominal wall (fistula from ruptured abscess)
• Genitourinary: Renal, prostatic, ovarian abscesses (very rare)

Host Immune Response

Innate Immunity:

• Mucosal barriers: Mucus layer, IgA, antimicrobial peptides (lysozyme, defensins)
• Neutrophils: Recruited but killed by amoeba before effective phagocytosis
• Macrophages: Activated but amoeba is resistant to oxidative burst
• Complement: Activated but amoeba evades membrane attack complex

Adaptive Immunity:

• Antibody response: IgG and mucosal IgA develop after invasion
  • Serology positive in 95% of ALA, 70% of colitis [16]
  • Antibodies persist for years (useful for diagnosis but not protective)
• Cell-mediated immunity: Th1 response (IFN-γ, TNF-α) associated with resistance
• Immune evasion: Amoeba suppresses effective immunity; reinfection is common

Why Some Develop Invasive Disease:

• Host factors: Genetic susceptibility (HLA-DR3, lectin polymorphisms), malnutrition, immunosuppression
• Parasite virulence: Strain variation in virulence factors (genotypes vary)
• Microbiome: Intestinal bacteria influence invasion; E. histolytica virulence enhanced by specific bacterial flora [14]

Classification of Amoebiasis

---

4. Clinical Presentation

Symptom Spectrum

The clinical presentation of amoebiasis is highly variable, ranging from completely asymptomatic cyst carriage to life-threatening invasive disease. [1,2]

Asymptomatic Intestinal Colonization (90% of E. histolytica infections):

• No symptoms
• Normal physical examination
• Cysts detected incidentally on stool examination or during screening
• Public health significance: Ongoing transmission reservoir

Amoebic Colitis (Intestinal Amoebiasis)

Typical Presentation:

Symptoms:

• Onset: Gradual (over days to 2-3 weeks) — NOT acute like bacterial dysentery
• Bloody diarrhea: 90-100% of symptomatic cases
  • Frank blood and mucus in stool ("raspberry jelly" stools)
  • "Frequency: 4-8 bowel movements per day (range 3-20+)"
  • Small volume with tenesmus
• Abdominal pain: 60-80% of cases
  • Cramping, colicky lower abdominal pain
  • Worse before bowel movements
• Tenesmus: 50-70% (painful urge with incomplete evacuation)
• Fever: 30-40% only (distinguishes from bacillary dysentery where fever is common)
• Weight loss: 40-50% with prolonged symptoms
• Nausea/vomiting: 20-30%

Physical Examination:

• General: Mild-moderate illness (not toxic appearance unless fulminant)
• Vital signs: Fever (38-39°C) in minority; tachycardia if dehydrated
• Abdominal examination:
  • Tenderness over colon (right lower quadrant > left lower quadrant)
  • No rigidity or rebound (unless perforation)
  • Hyperactive bowel sounds
• Rectal examination: Blood on glove; tenderness
• Dehydration signs: If severe diarrhea (dry mucous membranes, reduced skin turgor, hypotension)

Duration:

• Untreated: Symptoms wax and wane over weeks to months (chronic relapsing course)
• Treated: Resolution within 3-5 days of starting therapy

Differential Diagnosis of Bloody Diarrhea:

• Bacterial dysentery: Shigella, Campylobacter, Salmonella, enterohemorrhagic E. coli
  • More acute onset, higher fever, shorter duration
• Inflammatory bowel disease: Ulcerative colitis, Crohn's disease
  • More chronic course, extraintestinal manifestations
• Other parasites: Schistosomiasis, Balantidium coli
• Ischemic colitis: Older age, vascular disease, sudden onset
• Colorectal cancer: Older age, chronic symptoms, weight loss

Fulminant Amoebic Colitis (2-5% of Colitis Cases)

Presentation:

• Severe bloody diarrhea: Profuse, >10-20 stools/day
• Systemic toxicity: High fever, tachycardia, hypotension, altered mental state
• Abdominal distension: Toxic megacolon (colon diameter >6 cm)
• Peritonitis: If perforation (rigid abdomen, guarding, rebound)
• Shock: Hypovolemia, sepsis

Risk Factors:

• Corticosteroid use (iatrogenic worsening; can precipitate fulminant disease)
• Malnutrition
• Pregnancy (especially 3rd trimester)
• Young children
• Immunosuppression

Complications:

• Toxic megacolon (1-2%)
• Perforation (1%) — usually cecum or sigmoid
• Peritonitis
• Massive hemorrhage (rare)

Amoebic Liver Abscess (ALA)

Typical Presentation:

Symptoms:

• Right upper quadrant pain: 80-90% of cases
  • Dull, constant aching pain
  • May radiate to right shoulder (diaphragmatic irritation)
• Fever and rigors: 80-90%
  • High fever (38.5-40°C), often with chills
  • Intermittent or continuous
• Anorexia and weight loss: 60-80%
• Cough: 20-30% if right lobe abscess (diaphragmatic irritation, reactive pleural effusion)
• Pleuritic chest pain: 10-20% if pleural involvement
• Diarrhea: Only 20-30% (often absent; intestinal symptoms may have resolved weeks-months prior) [10]
• Nausea/vomiting: 30-40%

Physical Examination:

• Tender hepatomegaly: 50-80%
  • Liver edge palpable below costal margin
  • Point tenderness over abscess site
• Percussion tenderness: 60-80%
  • Gentle fist percussion over right lower ribs elicits pain
• Intercostal tenderness: Pain on palpation over overlying ribs
• Jaundice: Rare (5-10%) unless large abscess or biliary compression
• Respiratory signs:
  • Reduced breath sounds right base (pleural effusion, atelectasis)
  • Dullness to percussion
  • Pleural rub (if pleural involvement)
• Ascites: Rare unless rupture

Time Course:

• Incubation: 2 weeks to several months after intestinal infection (median 8-12 weeks)
• Symptom duration at presentation: Typically 2-4 weeks (range: days to months)
• Fever pattern: Intermittent high spikes or continuous

Complications of ALA:

• Rupture into peritoneum (6-9%): Acute peritonitis, shock
• Rupture into pleura (5-15%): Empyema, hepatobronchial fistula, expectoration of "anchovy pus"
• Rupture into pericardium (1-2%): Cardiac tamponade (high mortality, especially left lobe) [9]
• Secondary bacterial infection (5-10%): Pyogenic conversion (fever persists, worsening)
• Biliary rupture: Cholangitis (rare)

Rare Extraintestinal Presentations

Cerebral Amoebiasis (Brain Abscess):

• Incidence: less than 0.1% of amoebiasis cases
• Presentation: Headache, seizures, focal neurological deficits, altered consciousness
• Mortality: >70% even with treatment [15]
• Diagnosis: MRI/CT shows ring-enhancing lesion(s); often multiple

Pericardial Amoebiasis:

• Mechanism: Rupture of left lobe liver abscess into pericardium
• Presentation: Chest pain, dyspnea, Beck's triad (hypotension, muffled heart sounds, JVP elevation)
• Diagnosis: Echocardiography shows pericardial effusion ± tamponade
• Mortality: 40-60% [9]

Pleuropulmonary Amoebiasis:

• Mechanism: Extension from liver through diaphragm, or hematogenous spread
• Presentation: Cough, pleuritic pain, dyspnea, hemoptysis, expectoration of brownish sputum
• Imaging: Right-sided pleural effusion, lung abscess, hepatobronchial fistula

Cutaneous Amoebiasis:

• Mechanism: Fistula from ruptured abscess, or perianal spread
• Presentation: Painful, necrotic skin ulcers (perianal, abdominal wall)

Red Flags — Urgent Assessment Required

[!CAUTION] Red Flags Indicating Life-Threatening Complications:

• Peritonitis (rigid abdomen, guarding, rebound) → Perforation or ruptured abscess
• Toxic megacolon (abdominal distension >6 cm, systemic toxicity) → Surgical emergency
• Severe bloody diarrhea with shock (hypotension, tachycardia, oliguria) → Resuscitation needed
• Large liver abscess >10 cm → High rupture risk; consider drainage
• Left lobe liver abscess → Risk of pericardial rupture and tamponade [9]
• Neurological symptoms (altered consciousness, seizures, focal deficits) → Cerebral amoebiasis [15]
• Chest pain, dyspnea, muffled heart sounds → Pericardial rupture and tamponade
• Jaundice with liver abscess → Large abscess or biliary involvement
• Pregnancy (3rd trimester) with amoebiasis → Higher risk of fulminant colitis

---

5. Clinical Examination

Structured Approach

General Assessment

Inspection:

• General appearance: Degree of illness (mild-moderate colitis vs. toxic fulminant colitis)
• Hydration status: Dry mucous membranes, reduced skin turgor, sunken eyes
• Nutritional status: Weight loss, muscle wasting (chronic disease)
• Jaundice: Rare; suggests large liver abscess or biliary involvement
• Respiratory distress: If pleural or pericardial involvement

Vital Signs:

• Fever: Present in 30-40% of colitis, 80-90% of ALA
• Pulse: Tachycardia if dehydrated, febrile, or septic
• Blood pressure: Hypotension if hypovolemic shock or rupture
• Respiratory rate: Tachypnea if respiratory complications or metabolic acidosis
• Oxygen saturation: Reduced if pleural effusion, pneumonia, or sepsis

Abdominal Examination

Inspection:

• Distension: Toxic megacolon (measure abdominal girth if suspected)
• Surgical scars: Previous abdominal surgery
• Visible peristalsis: Bowel obstruction (amoeboma)

Palpation:

• Amoebic colitis:
  • Tenderness over colon (right lower quadrant, left lower quadrant)
  • No masses unless amoeboma
  • No guarding or rigidity (unless perforation)
• Amoebic liver abscess:
  • "Hepatomegaly: Liver edge palpable below right costal margin (50-80%)"
  • "Point tenderness: Localized pain over abscess site (right upper quadrant)"
  • "Liver span: Increased (normal 6-12 cm in midclavicular line)"

Percussion:

• Hepatic percussion: Liver span increased in ALA
• Percussion tenderness: Punch tenderness over liver (60-80% of ALA)
  • "Technique: Gentle fist percussion over right lower ribs → pain"
• Shifting dullness: Ascites if ruptured abscess (rare)

Auscultation:

• Bowel sounds: Hyperactive (colitis) vs. reduced/absent (toxic megacolon, perforation)

Respiratory Examination

Inspection:

• Reduced chest expansion: Right lower chest if pleural effusion or diaphragmatic splinting

Palpation:

• Chest wall tenderness: Intercostal tenderness over liver in ALA

Percussion:

• Dullness at right base: Pleural effusion, hepatomegaly elevating diaphragm

Auscultation:

• Reduced breath sounds: Right base (effusion, atelectasis)
• Pleural rub: If pleural inflammation

Cardiovascular Examination

Auscultation:

• Muffled heart sounds: Pericardial effusion or tamponade (ruptured left lobe abscess) [9]

Inspection:

• Jugular venous pressure (JVP): Elevated if pericardial tamponade

Special Tests

---

6. Investigations

Diagnostic Strategy

Diagnosis of amoebiasis requires integration of clinical, laboratory, and imaging findings. Key principles: [1,2,16]

1. Distinguish E. histolytica from E. dispar: Requires antigen detection or PCR (not microscopy alone)
2. Direct detection: Stool microscopy, stool antigen, stool PCR
3. Indirect detection: Serology (antibodies) — high sensitivity for ALA
4. Imaging: Ultrasound or CT for liver abscess
5. Aspiration: Reserved for select cases (uncertain diagnosis, large abscess)

First-Line Investigations

Stool Microscopy:

• Fresh stool sample (within 30 minutes) or preserved in polyvinyl alcohol (PVA)
• Multiple samples: 3 stool specimens on separate days (increases sensitivity to 85-95%)
• Findings:
  • "Trophozoites: Motile, 10-60 μm, single nucleus, ingested RBCs (pathognomonic) [5]"
  • "Cysts: Quadrinucleate, 10-15 μm"
• Limitations: Cannot distinguish E. histolytica from E. dispar morphologically
• Sensitivity: 50-60% for colitis (single sample); 10-20% for ALA (diarrhea often absent) [10]

Stool Antigen Detection (ELISA):

• E. histolytica-specific antigen: Gal/GalNAc lectin
• Sensitivity: 85-95% for E. histolytica in stool
• Specificity: >95% (distinguishes from E. dispar)
• Advantages: Rapid (24-48 hours), does not require fresh stool
• Limitations: Detects current infection only (not past infection)

Stool PCR:

• Target: E. histolytica-specific DNA sequences
• Sensitivity: 90-100%
• Specificity: >98%
• Advantages: Definitively distinguishes E. histolytica from E. dispar [5]
• Limitations: Not widely available; higher cost

Serology (Antibody Detection):

• Methods: ELISA, indirect hemagglutination assay (IHA), immunofluorescence
• Sensitivity:
  • "Amoebic liver abscess: 95% (within 7-10 days of symptom onset) [16]"
  • "Amoebic colitis: 70%"
  • "Asymptomatic colonization: 10-20%"
• Specificity: 90-95%
• Limitations:
  • Cannot distinguish past from current infection (antibodies persist for years)
  • Low sensitivity in endemic areas (high background seropositivity)
• Clinical use: Most useful for ALA diagnosis, especially if stool negative

Laboratory Tests

Key Laboratory Distinctions:

• Amoebiasis vs. Pyogenic Liver Abscess:
  • "Amoebiasis: Serology positive, blood cultures negative, lower neutrophil count"
  • "Pyogenic: Serology negative, blood cultures positive (50-70%), very high WBC"
• Amoebiasis vs. Helminth Infection:
  • "Amoebiasis: NO eosinophilia"
  • "Helminths: Eosinophilia common"

Imaging Investigations

Ultrasound Abdomen:

Indications: First-line imaging for suspected ALA

Findings in ALA:

• Round/oval hypoechoic lesion: 2-20 cm diameter (median 5-10 cm)
• Location: Right lobe (75-80%), subcapsular > left lobe (20%) [9]
• Internal echoes: Homogeneous or heterogeneous low-level echoes
• Wall: No distinct wall (unlike pyogenic abscess which has thick wall)
• Posterior acoustic enhancement: Increased through-transmission (fluid-filled)
• Number: Solitary (85%), multiple (15%)

Advantages:

• Portable, non-invasive, no radiation
• Can guide drainage if required

Limitations:

• Operator-dependent
• Cannot distinguish amoebic from pyogenic abscess reliably

CT Abdomen with Contrast:

Indications:

• Confirm ALA diagnosis
• Assess complications (rupture, secondary infection)
• Pre-operative planning

Findings in ALA:

• Well-defined, round, low-attenuation lesion (10-20 Hounsfield units)
• Rim enhancement with IV contrast (peripheral hypervascular rim)
• "Double target sign": Inner ring (abscess wall) + outer ring (compressed liver)
• Location and number: As per ultrasound

Advantages:

• Better characterization than ultrasound
• Detects complications (rupture, pleural involvement)
• Assesses other pathology

Limitations:

• Radiation exposure
• Cannot definitively distinguish amoebic from pyogenic

Chest X-ray:

Indications: All cases of ALA to detect thoracic complications

Findings:

• Elevated right hemidiaphragm (50-60% of ALA)
• Right-sided pleural effusion (20-30%)
• Right lower lobe atelectasis (10-20%)
• Subphrenic gas (if ruptured abscess)
• Hepatobronchial fistula (air-fluid level in liver abscess)

Colonoscopy:

Indications:

• Uncertain diagnosis (differentiate from inflammatory bowel disease, colon cancer)
• Amoeboma (mass lesion)

Findings in Amoebic Colitis:

• Flask-shaped ulcers: Discrete ulcers with normal intervening mucosa
• Distribution: Patchy, often cecum and ascending colon > rectosigmoid
• Biopsy: Trophozoites at ulcer edge (PAS stain positive)

Risks:

• Perforation risk in severe colitis (relative contraindication if fulminant)

Diagnostic Aspiration of Liver Abscess

Indications (Selective):

• Uncertain diagnosis: Cannot distinguish amoebic from pyogenic abscess
• No response to treatment after 48-72 hours of metronidazole
• Large abscess >10 cm: Therapeutic drainage
• Left lobe abscess: Risk of pericardial rupture [9]
• Secondary bacterial infection suspected: Persistent fever despite treatment

Procedure:

• Ultrasound-guided percutaneous aspiration: Safer than blind aspiration
• Send aspirate for:
  • Bacterial culture and sensitivity (sterile in amoebiasis) [7]
  • Gram stain
  • AFB stain and culture (TB abscess in differential)
  • Trophozoite examination (rarely positive; trophozoites at abscess wall, not center)

Findings in ALA:

• "Anchovy paste" or "chocolate sauce" appearance: Reddish-brown, odorless, thick [7]
• Sterile on bacterial culture (unless secondary bacterial infection)
• Trophozoites: Rarely seen in aspirate (at wall, not in necrotic pus)

Complications:

• Bleeding
• Peritoneal spillage
• Secondary infection

Diagnostic Algorithm

SUSPECTED AMOEBIASIS
         ↓
┌────────────────────────────┐
│ CLINICAL PRESENTATION      │
│ - Bloody diarrhea          │
│ - Travel history           │
│ - RUQ pain + fever         │
└────────────────────────────┘
         ↓
┌────────────────────────────────────────┐
│ INTESTINAL SYMPTOMS?                   │
├────────────────────────────────────────┤
│ YES → Stool investigations:            │
│       1. Microscopy (fresh, 3 samples) │
│       2. Stool antigen (E. histolytica)│
│       3. Stool PCR (if available)      │
│       4. Stool bacterial culture (DDx) │
│ NO → Likely extraintestinal            │
└────────────────────────────────────────┘
         ↓
┌────────────────────────────────────────┐
│ LIVER ABSCESS SUSPECTED? (RUQ pain)    │
├────────────────────────────────────────┤
│ YES → 1. Ultrasound abdomen            │
│       2. Amoebic serology              │
│       3. Chest X-ray                   │
│       4. FBC, LFTs, blood cultures     │
│ NO → Consider other diagnoses          │
└────────────────────────────────────────┘
         ↓
┌────────────────────────────────────────┐
│ DIAGNOSIS CONFIRMED?                   │
├────────────────────────────────────────┤
│ YES → Treat (see Management)           │
│ UNCERTAIN → CT abdomen OR aspiration   │
└────────────────────────────────────────┘

---

7. Management

Principles of Treatment

1. Dual therapy mandatory: Tissue amoebicide (kills invasive trophozoites) + Luminal amoebicide (eradicates intestinal cysts) [6]
2. Sequential administration: Tissue agent first, then luminal agent
3. Supportive care: Rehydration, nutrition, analgesia
4. Drainage: Selective indications (large abscess, uncertain diagnosis, treatment failure)
5. Surgery: Reserved for complications (perforation, toxic megacolon, rupture)

Medical Management

Tissue Amoebicides (Kill Invasive Trophozoites)

Metronidazole (First-line)

• Dose:
  • "Amoebic colitis: 750-800 mg orally TDS (three times daily) for 7-10 days"
  • "Amoebic liver abscess: 750-800 mg orally TDS (or 500 mg IV TDS if unable to take oral) for 7-10 days"
  • "Children: 35-50 mg/kg/day divided TDS for 7-10 days"
• Mechanism: Nitro-reduction in anaerobic organisms → DNA damage
• Efficacy: 90-95% cure rate for ALA; >95% for colitis [6]
• Adverse effects: Metallic taste, nausea, disulfiram-like reaction with alcohol
• Contraindications: First trimester pregnancy (relative; use if severe disease)

Tinidazole (Alternative)

• Dose:
  • "Colitis: 2 g orally once daily for 3-5 days"
  • "ALA: 2 g orally once daily for 5 days (or 600 mg BD for 5 days)"
  • "Children: 50 mg/kg/day (max 2 g) once daily for 3-5 days"
• Advantages: Better tolerated than metronidazole; shorter course; once-daily dosing
• Efficacy: Equivalent to metronidazole
• Adverse effects: Similar to metronidazole but less frequent

[!IMPORTANT] Tissue amoebicides (metronidazole/tinidazole) do NOT eliminate intestinal cysts. Failure to follow with a luminal amoebicide results in 40-60% recurrence rates and continued cyst shedding, perpetuating transmission. [6]

Luminal Amoebicides (Eliminate Intestinal Cysts)

Always administer AFTER tissue amoebicide to prevent relapse and transmission.

Paromomycin (First-line luminal agent)

• Dose:
  • "Adults: 500 mg orally TDS for 7 days"
  • "Children: 25-35 mg/kg/day divided TDS for 7 days"
• Mechanism: Aminoglycoside; acts on luminal trophozoites and cysts
• Efficacy: 85-95% eradication of cysts [6]
• Adverse effects: Gastrointestinal upset (nausea, diarrhea); minimal systemic absorption
• Safety: Safe in pregnancy (not absorbed systemically)

Diloxanide Furoate (Alternative)

• Dose:
  • "Adults: 500 mg orally TDS for 10 days"
  • "Children: 20 mg/kg/day divided TDS for 10 days"
• Efficacy: 80-90% cyst eradication
• Adverse effects: Flatulence, nausea (generally well-tolerated)
• Availability: Not available in all countries (common in UK, unavailable in USA)

Iodoquinol (Second-line)

• Dose:
  • "Adults: 650 mg orally TDS for 20 days"
  • "Children: 30-40 mg/kg/day (max 2 g/day) divided TDS for 20 days"
• Adverse effects: Optic neuropathy, peripheral neuropathy (rare; with prolonged use)
• Contraindications: Iodine allergy, thyroid disease

Treatment Regimens by Clinical Scenario

Asymptomatic Intestinal Colonization (Cyst Carrier):

• Indication: Positive stool antigen/PCR for E. histolytica but no symptoms
• Treatment: Luminal amoebicide ONLY (paromomycin or diloxanide)
• Rationale: No invasive disease; eradicate cysts to prevent transmission

Amoebic Colitis (Mild-Moderate):

1. Metronidazole 750-800 mg PO TDS × 7-10 days
   • OR Tinidazole 2 g PO once daily × 3-5 days
2. THEN Paromomycin 500 mg PO TDS × 7 days
   • OR Diloxanide 500 mg PO TDS × 10 days

Supportive Care:

• Oral rehydration solution (ORS)
• Antimotility agents: AVOID (may precipitate toxic megacolon)
• Analgesia: Paracetamol (avoid NSAIDs; risk of perforation)

Fulminant Amoebic Colitis:

1. Resuscitation: IV fluids, electrolyte correction
2. Metronidazole 500 mg IV TDS × 7-10 days
3. Broad-spectrum antibiotics: Add empiric Gram-negative coverage (risk of perforation/translocation)
   • Example: Ceftriaxone 1-2 g IV daily
4. Surgical consultation: High risk of perforation, toxic megacolon
5. THEN Paromomycin 500 mg PO TDS × 7 days (once stable, tolerating oral)

Amoebic Liver Abscess (ALA):

1. Metronidazole 750-800 mg PO TDS × 7-10 days (or 500 mg IV TDS if unable to take oral)
   • OR Tinidazole 2 g PO once daily × 5 days
2. THEN Paromomycin 500 mg PO TDS × 7 days
   • OR Diloxanide 500 mg PO TDS × 10 days

Response to Treatment:

• Fever: Defervescence within 48-72 hours (90% of cases) [10]
• Pain: Improvement within 3-5 days
• Abscess size: Gradual reduction over 3-6 months (imaging resolution lags clinical improvement)
• If no response by 72 hours: Consider drainage or alternative diagnosis (pyogenic abscess)

Supportive Care:

• Analgesia (paracetamol, opioids if severe)
• Nutrition support
• Antiemetics if vomiting

Aspiration/Drainage of Liver Abscess

Indications:

Methods:

• Percutaneous needle aspiration: Single aspiration; may need repeat
• Percutaneous catheter drainage: Pigtail catheter; leave in situ until output less than 10 mL/day
• Open surgical drainage: Rarely needed (rupture with peritonitis)

Outcome:

• Drainage + metronidazole: Cure rate >95%
• Medical therapy alone: 90-95% cure rate (drainage not routinely required) [10]

Surgical Management

Indications:

Perioperative Considerations:

• Continue metronidazole perioperatively
• Broad-spectrum antibiotics for bacterial superinfection
• High mortality if delayed intervention (ruptured abscess mortality 20-30% vs. less than 1% if treated before rupture)

Special Populations

Pregnancy:

• First trimester: Paromomycin alone (not systemically absorbed) for mild disease
  • Metronidazole reserved for severe/life-threatening disease (teratogenicity risk)
• Second/third trimester: Metronidazole safe if required
• Risk: Higher rate of fulminant colitis in 3rd trimester
• ALA in pregnancy: Metronidazole + drainage if indicated

Children:

• Dose adjustments (mg/kg) as above
• Higher risk of dehydration; aggressive rehydration
• Same dual therapy principle applies

Immunocompromised (HIV, transplant, corticosteroids):

• Higher risk of fulminant disease
• Same treatment regimens, but lower threshold for IV therapy and admission
• Corticosteroid use: Can precipitate fulminant colitis; avoid steroids if amoebiasis suspected

Men Who Have Sex with Men (MSM):

• Higher prevalence of intestinal amoebiasis [12]
• Screen sexual contacts
• Treat asymptomatic carriers to prevent transmission

Disposition and Follow-Up

Admission Indications:

• Severe colitis (frequent bloody stools, dehydration, systemic toxicity)
• Fulminant colitis or toxic megacolon
• Amoebic liver abscess (most cases for initial management)
• Complications (perforation, rupture, shock)
• Inability to tolerate oral therapy
• Social factors (unreliable follow-up, homelessness)

Outpatient Management (if appropriate):

• Mild-moderate colitis, tolerating oral fluids
• Small uncomplicated ALA (less than 5 cm) if reliable follow-up
• Close follow-up at 48-72 hours to ensure clinical response

Follow-Up:

Expected Outcomes:

• Fever: Resolves within 48-72 hours in 90% of ALA cases [10]
• Diarrhea: Resolves within 3-5 days of treatment
• Abscess size: Gradual reduction; may take 3-12 months for complete resolution
• Persistent lesion: Up to 10% have persistent radiological abnormality (calcified scar) despite cure

Management Algorithm

CONFIRMED AMOEBIASIS
         ↓
┌──────────────────────────────────────────┐
│ ASSESS SEVERITY                          │
├──────────────────────────────────────────┤
│ MILD-MODERATE                            │
│ - Outpatient management                  │
│ - Oral therapy                           │
│                                          │
│ SEVERE/COMPLICATED                       │
│ - Admit                                  │
│ - IV therapy, resuscitation              │
└──────────────────────────────────────────┘
         ↓
┌──────────────────────────────────────────┐
│ INITIAL TREATMENT (Tissue Amoebicide)    │
├──────────────────────────────────────────┤
│ Option 1: Metronidazole 750-800mg TDS   │
│           PO/IV × 7-10 days              │
│                                          │
│ Option 2: Tinidazole 2g OD × 3-5 days   │
└──────────────────────────────────────────┘
         ↓
┌──────────────────────────────────────────┐
│ ASSESS RESPONSE at 48-72h                │
├──────────────────────────────────────────┤
│ GOOD (fever↓, pain↓, diarrhea↓)         │
│ → Continue treatment                     │
│                                          │
│ POOR (persistent fever, worsening)       │
│ → ALA: Consider drainage                 │
│ → Colitis: Consider complications        │
└──────────────────────────────────────────┘
         ↓
┌──────────────────────────────────────────┐
│ COMPLETE TISSUE AMOEBICIDE COURSE        │
└──────────────────────────────────────────┘
         ↓
┌──────────────────────────────────────────┐
│ THEN: Luminal Amoebicide (MANDATORY)     │
├──────────────────────────────────────────┤
│ Option 1: Paromomycin 500mg TDS × 7d    │
│                                          │
│ Option 2: Diloxanide 500mg TDS × 10d    │
└──────────────────────────────────────────┘
         ↓
┌──────────────────────────────────────────┐
│ FOLLOW-UP                                │
│ - Stool clearance (2-4 weeks)           │
│ - Imaging (3-6 months for ALA)          │
└──────────────────────────────────────────┘

---

8. Complications

Intestinal Complications

Risk Factors for Severe Intestinal Complications:

• Corticosteroid use (iatrogenic worsening)
• Malnutrition
• Pregnancy (especially 3rd trimester)
• Extremes of age (less than 5 years, >60 years)
• Immunosuppression (HIV, chemotherapy)
• Delayed diagnosis/treatment

Liver Abscess Complications

Rupture (Most Common Complication):

Other Hepatic Complications:

• Secondary bacterial infection (5-10%): Pyogenic conversion; fever persists despite metronidazole; requires aspiration, culture, antibiotics
• Hepatic vein thrombosis (less than 1%): Budd-Chiari syndrome; requires anticoagulation
• Inferior vena cava thrombosis (rare): Large right lobe abscess compressing IVC

Factors Associated with Rupture:

• Large abscess size (>10 cm)
• Left lobe location (higher risk of pericardial rupture) [9]
• Thin abscess wall (less than 1 cm)
• Subcapsular location
• Delayed treatment

Extraintestinal Dissemination (Rare Sites)

Cerebral Amoebiasis (Brain Abscess):

• Incidence: less than 0.1% of amoebiasis cases
• Route: Hematogenous spread from liver or intestine
• Presentation: Headache, fever, seizures, focal neurological deficits, altered consciousness
• Imaging: CT/MRI shows single or multiple ring-enhancing lesions
• Diagnosis: Serology positive; brain biopsy rarely performed
• Treatment: High-dose metronidazole (up to 2.4 g/day) for prolonged duration (4-6 weeks); ± surgical drainage if accessible
• Mortality: >70% even with treatment [15]

Pleuropulmonary Amoebiasis:

• Routes: Direct extension from liver through diaphragm (most common), or hematogenous
• Presentations:
  • Pleural effusion/empyema (most common)
  • Lung abscess
  • Hepatobronchial fistula (expectoration of brownish sputum)
• Treatment: Metronidazole + chest drainage if empyema
• Mortality: 5-15%

Pericardial Amoebiasis:

• Route: Rupture of left lobe liver abscess into pericardium
• Presentation: Cardiac tamponade (Beck's triad: hypotension, muffled heart sounds, elevated JVP), chest pain
• Diagnosis: Echocardiography (pericardial effusion)
• Treatment: Emergency pericardiocentesis or surgical pericardial window + metronidazole
• Mortality: 40-60% [9]

Cutaneous Amoebiasis:

• Routes: Fistula from ruptured abscess, or direct perianal spread in colitis
• Presentation: Painful, rapidly expanding necrotic skin ulcers (perianal, abdominal wall, perineum)
• Treatment: Metronidazole; local wound care; surgical debridement if extensive
• Prognosis: Good if treated

Genitourinary Amoebiasis (Very Rare):

• Sites: Kidney, bladder, prostate, uterus, ovaries
• Presentation: Hematuria, pelvic pain, dysuria
• Treatment: Metronidazole ± drainage

Mortality and Morbidity Summary

---

9. Prognosis & Outcomes

Natural History (Untreated)

Asymptomatic Colonization:

• Spontaneous clearance: 10-20% clear infection spontaneously within 12 months
• Persistent carriage: 80-90% remain asymptomatic carriers for years (ongoing cyst shedding)
• Progression to invasive disease: 10% develop symptomatic disease over lifetime

Amoebic Colitis:

• Spontaneous resolution: Rare (less than 5%)
• Chronic relapsing course: Waxing and waning symptoms over weeks to months (most common)
• Progression to fulminant disease: 2-5% (higher in immunocompromised, malnourished, pregnancy)
• Mortality (untreated): 2-5% overall; 50-70% if fulminant

Amoebic Liver Abscess:

• Spontaneous resolution: Exceedingly rare
• Progression: Gradual enlargement → rupture (20-30% if untreated)
• Mortality (untreated): 10-30%; >70% if ruptured

Outcomes with Treatment

Amoebic Colitis:

Amoebic Liver Abscess:

Prognostic Factors

Good Prognosis (Lower Mortality/Complications):

• Early diagnosis and treatment
• Uncomplicated intestinal or hepatic disease
• Right lobe liver abscess (vs. left lobe) [9]
• Single abscess (vs. multiple)
• Abscess size less than 10 cm
• Young age (20-40 years)
• Immunocompetent
• Good nutritional status
• Prompt response to metronidazole (defervescence less than 72 hours)

Poor Prognosis (Higher Mortality/Complications):

• Delayed diagnosis or treatment
• Fulminant colitis or toxic megacolon
• Bowel perforation
• Large abscess (>10 cm)
• Left lobe abscess (pericardial rupture risk) [9]
• Multiple abscesses
• Ruptured abscess (peritoneal, pleural, pericardial)
• Extraintestinal dissemination (cerebral, pericardial) [9,15]
• Extremes of age (less than 5 years, >60 years)
• Immunosuppression (HIV, corticosteroids, chemotherapy)
• Malnutrition
• Pregnancy (3rd trimester)
• Secondary bacterial infection
• Failure to respond to metronidazole within 72 hours

Long-Term Outcomes

Post-Treatment:

• Immunity: Antibodies persist for years but are NOT protective; reinfection is common with re-exposure
• Chronic symptoms: Rare; post-infectious IBS may occur (less than 5%)
• Abscess resolution: Radiological resolution lags clinical cure; may take 3-12 months
• Recurrence: less than 5% if dual therapy completed; 40-60% if luminal agent omitted [6]
• Sequelae:
  • Intestinal stricture (1-2%)
  • Chronic hepatic calcification (asymptomatic; 10%)

Quality of Life:

• Full recovery expected with appropriate treatment
• No long-term disability if uncomplicated

---

10. Prevention & Public Health

Primary Prevention

Water and Food Safety:

• Boil water: Bring to rolling boil for 1 minute (3 minutes at high altitude) to kill cysts
• Filtration: Use filters with less than 1 μm pore size
• Avoid:
  • Tap water in endemic areas (including ice cubes)
  • Raw vegetables and salads (unless washed with safe water and peeled)
  • Street food
  • Unpasteurized dairy products
• Safe foods: Cooked foods served hot, bottled water, peeled fruits

Sanitation and Hygiene:

• Hand hygiene: Soap and water after defecation, before eating/food preparation
• Sanitary waste disposal: Proper sewage systems, latrines
• Food handler screening: In endemic areas, screen food handlers; treat carriers

Travel Advice:

• High-risk destinations: South Asia, Central/South America, Sub-Saharan Africa
• Chemoprophylaxis: Not recommended (no effective prophylactic agent)
• Traveler precautions: Bottled water, avoid raw foods, hand hygiene

Secondary Prevention (Screening and Treatment of Asymptomatic Carriers)

Indications for Screening:

• Returning travelers from endemic areas with gastrointestinal symptoms
• Household contacts of confirmed cases
• Food handlers in endemic areas
• Men who have sex with men (MSM) with GI symptoms [12]
• Immigrants/refugees from endemic regions (if symptomatic or high-risk occupation)

Screening Method:

• Stool antigen detection (E. histolytica-specific) or stool PCR
• NOT stool microscopy alone (cannot distinguish E. histolytica from E. dispar) [5]

Treatment of Asymptomatic Carriers:

• Luminal amoebicide alone (paromomycin or diloxanide)
• Rationale: Prevent progression to invasive disease; interrupt transmission

Tertiary Prevention (Preventing Complications in Diagnosed Cases)

• Complete dual therapy: Prevent relapse by ensuring luminal agent is given [6]
• Early drainage of large or left lobe abscesses: Prevent rupture [9]
• Avoid corticosteroids: Do not give steroids if amoebiasis suspected (can precipitate fulminant colitis)
• Close monitoring: 48-72 hour review to ensure treatment response

Public Health Measures

Surveillance:

• Amoebiasis is a notifiable disease in many countries
• Epidemiological tracking to identify outbreaks and high-risk areas

Outbreak Investigation:

• Common source outbreaks (contaminated water supply)
• Screen and treat contacts
• Environmental investigation and remediation

Health Education:

• Community education on water safety, sanitation, hand hygiene
• Traveler education on food and water precautions

---

11. Evidence & Guidelines

Key Guidelines

1. World Health Organization (WHO):

• Guidelines for Drinking-water Quality (2022): Recommendations on water treatment to prevent parasitic infections including amoebiasis
• Prevention and Control of Intestinal Parasitic Infections (WHO Technical Report Series): Public health measures

2. Centers for Disease Control and Prevention (CDC):

• CDC Yellow Book — Traveler's Health: Amebiasis prevention and treatment for travelers
• DPDx — Laboratory Identification of Parasites: Diagnostic guidelines for E. histolytica
• Available: cdc.gov/parasites/amebiasis

3. Infectious Diseases Society of America (IDSA):

• No specific amoebiasis guideline currently published
• Treatment recommendations in general parasitic disease guidelines

4. British Society of Gastroenterology (BSG):

• Guidelines on management of acute diarrhea and colitis (includes parasitic causes)

5. Cochrane Reviews:

• Metronidazole for amoebic liver abscess: Supports metronidazole as first-line therapy

Landmark Studies & Key Evidence

1. Haque R, et al. Amebiasis. N Engl J Med 2003;348:1565-73. [PMID: 12700377]

• Type: Comprehensive review
• Key findings: Landmark review distinguishing E. histolytica (pathogenic) from E. dispar (non-pathogenic); epidemiology, pathogenesis, diagnosis, treatment
• Clinical impact: Established modern understanding of amoebiasis; emphasized need for species-specific diagnosis [2]

2. Stanley SL Jr. Amoebiasis. Lancet 2003;361:1025-34. [PMID: 12660071]

• Type: Review
• Key findings: Detailed pathogenesis of E. histolytica invasion; virulence factors (Gal/GalNAc lectin, amoebapores, cysteine proteases)
• Clinical impact: Foundation for understanding molecular mechanisms of tissue invasion [1]

3. Blessmann J, et al. Real-time PCR for detection and differentiation of Entamoeba histolytica and Entamoeba dispar in fecal samples. J Clin Microbiol 2002;40:4413-7. [PMID: 12454130]

• Type: Diagnostic study
• Key findings: PCR reliably distinguishes E. histolytica from E. dispar (sensitivity 90-100%, specificity >98%)
• Clinical impact: Established molecular diagnostics as gold standard; prevents overtreatment of non-pathogenic E. dispar [5]

4. Petri WA Jr, Haque R, et al. Estimating the impact of amebiasis on health. Parasitol Today 2000;16:320-1.

• Type: Epidemiological analysis
• Key findings: Global burden of amoebiasis: 50 million symptomatic cases, 40,000-100,000 deaths annually
• Clinical impact: Quantified global health impact; third leading parasitic cause of death [3]

5. Fu CJ, et al. Global burden and trends of Entamoeba infection-associated diseases from 1990 to 2019. Acta Trop 2023;238:106801. [PMID: 36801451]

• Type: Systematic review and meta-analysis
• Key findings: Analyzed Global Burden of Disease data; highest burden in South Asia, Central America, Africa; male predominance in ALA
• Clinical impact: Updated epidemiology and disease trends over 30 years [4]

6. Gonzales MLM, et al. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev 2009;(2):CD006085.

• Type: Cochrane systematic review
• Key findings: Metronidazole/tinidazole effective for invasive amoebiasis; luminal agent required to prevent relapse
• Clinical impact: Evidence base for dual therapy (tissue + luminal amoebicide) [6]

7. Stanley SL Jr. The Entamoeba histolytica cysteine proteinases: structure, function, and pathogenesis. Arch Med Res 2006;37:222-3.

• Type: Review
• Key findings: Cysteine proteases degrade extracellular matrix, mucus, antibodies; enable tissue invasion
• Clinical impact: Understanding virulence mechanisms guides potential therapeutic targets [13]

8. Newman KL, et al. Sexually transmitted enteric infections in men who have sex with men. Clin Microbiol Rev 2025. [PMID: 40960298]

• Type: Comprehensive review
• Key findings: Higher prevalence of intestinal amoebiasis in MSM population via faecal-oral transmission
• Clinical impact: Identified high-risk population requiring targeted screening and education [12]

9. Oliveira FM, et al. Amoebic liver abscess in children: case series and literature review. Pediatr Infect Dis J 2011;30:1019-21.

• Type: Case series and review
• Key findings: Left lobe abscesses have higher mortality due to pericardial rupture risk
• Clinical impact: Guides decision for early drainage of left lobe abscesses [9]

10. Lodhi S, et al. Features distinguishing amoebic from pyogenic liver abscess: a review of 577 adult cases. Trop Med Int Health 2004;9:718-23.

• Type: Retrospective cohort
• Key findings: ALA: younger age, single abscess, positive serology, sterile pus, fever defervescence less than 72h with metronidazole
• Clinical impact: Clinical predictors to distinguish amoebic from pyogenic abscess [7,10]

11. Fotedar R, et al. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev 2007;20:511-32.

• Type: Review
• Key findings: Stool microscopy alone insufficient; antigen detection and PCR required for species differentiation
• Clinical impact: Emphasized diagnostic stewardship; avoid overdiagnosis and overtreatment [16]

12. Ximénez C, et al. Epidemiology of intestinal parasites in Mexico. Salud Publica Mex 2011;53:S96-S106.

• Type: Epidemiological study
• Key findings: 90% of Entamoeba infections are non-pathogenic E. dispar
• Clinical impact: Highlights importance of species-specific diagnosis to avoid unnecessary treatment

13. Costa DM, et al. Entamoeba histolytica: Plasma membrane components and virulence factors in the invasive process. Curr Top Membr 2025;95:105-135. [PMID: 40774757]

• Type: Review
• Key findings: Detailed mechanisms of Gal/GalNAc lectin, amoebapores, cysteine proteases in tissue invasion
• Clinical impact: Molecular understanding of pathogenicity; potential therapeutic targets [14]

14. Zhao X, et al. Multi-omics insights into metabolic reprogramming of host cells triggered by Entamoeba histolytica. Microbiol Spectr 2025. [PMID: 40833094]

• Type: Multi-omics study
• Key findings: E. histolytica alters host cell metabolism to facilitate invasion; microbiome interactions modulate virulence
• Clinical impact: Novel insights into host-parasite interactions [14]

15. Petri WA Jr, Haque R. Entamoeba histolytica brain abscess. Handb Clin Neurol 2013;114:147-52. [PMID: 23829905]

• Type: Review
• Key findings: Cerebral amoebiasis mortality >70%; requires prolonged high-dose metronidazole
• Clinical impact: Highlighted worst prognosis of extraintestinal sites [15]

16. Tanyuksel M, Petri WA Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev 2003;16:713-29.

• Type: Review
• Key findings: Serology 95% sensitive for ALA, 70% for colitis; useful adjunct to stool diagnostics
• Clinical impact: Established role of serology in diagnosis, especially for ALA [16]

Evidence Strength Summary

Level of Evidence:

• 1a: Systematic reviews/meta-analyses of RCTs
• 1b: Individual RCTs
• 2a: Systematic reviews of cohort studies
• 2b: Individual cohort studies
• 3: Case-control studies, case series
• 4: Expert opinion

---

12. Differential Diagnosis

Amoebic Colitis — Differential Diagnoses

Amoebic Liver Abscess — Differential Diagnoses

---

13. Patient/Layperson Explanation

What is Amoebiasis?

Amoebiasis is an infection caused by a microscopic parasite called Entamoeba histolytica. You catch it by swallowing the parasite in contaminated water or food, usually in countries with poor sanitation. The parasite can cause two main types of illness:

1. Intestinal infection (amoebic dysentery): The parasite infects your gut, causing bloody diarrhea with cramping pain.
2. Liver abscess: The parasite travels to your liver and forms a collection of pus (an abscess), causing pain under your ribs on the right side and fever.

Most people who get infected don't have any symptoms but can still pass the infection to others.

Why Does It Matter?

• Common worldwide: About 50 million people get sick from this parasite every year, and it causes 40,000-100,000 deaths (mainly in developing countries).
• Travelers at risk: You can catch it when traveling to parts of Asia, Africa, or Central/South America.
• Treatable: The good news is that with the right antibiotics, amoebiasis is completely curable.
• Complications if untreated: Without treatment, liver abscesses can burst, and intestinal infection can cause serious damage.

How Do You Catch It?

You swallow the parasite (in the form of microscopic cysts) from:

• Contaminated water: Drinking untreated water, ice cubes
• Contaminated food: Raw vegetables, salads, food prepared by infected food handlers
• Poor hygiene: Not washing hands after using the toilet

The parasite is NOT spread through coughing, sneezing, or casual contact.

What Are the Symptoms?

Intestinal infection (amoebic colitis):

• Bloody diarrhea (blood and mucus in your stools)
• Cramping tummy pain (usually lower abdomen)
• Painful bowel movements
• Sometimes fever and weight loss
• Symptoms come on gradually over days to weeks (not sudden like food poisoning)

Liver abscess:

• Pain under your ribs on the right side (may spread to your shoulder)
• High fever and chills
• Loss of appetite and weight loss
• Often NO diarrhea (the gut infection may have been weeks or months earlier)

How Is It Diagnosed?

• Stool sample: Your doctor checks your poop for the parasite under a microscope or with a special test.
• Blood test: Checks for antibodies to the parasite (very useful for liver abscess).
• Ultrasound or CT scan: If liver abscess is suspected, imaging shows the collection of pus in your liver.

How Is It Treated?

Two medicines are needed — this is very important:

1. First medicine (metronidazole or tinidazole): Kills the parasites that are causing damage in your gut or liver. You take this for 7-10 days.
2. Second medicine (paromomycin or diloxanide): Clears the parasites still living in your intestine. You take this for 7-10 days AFTER the first medicine.

Why both? The first medicine kills the parasites making you sick, but doesn't clear them from your gut. Without the second medicine, the infection can come back, and you can still pass it to others.

For liver abscess: Sometimes the doctor needs to drain the pus with a needle (guided by ultrasound), especially if the abscess is large.

What to Expect During Treatment

• Fever usually goes away within 2-3 days of starting treatment.
• Diarrhea stops within 3-5 days.
• Liver abscess shrinks slowly over weeks to months (but you'll feel better much sooner).
• You MUST complete both courses of medicine to prevent the infection coming back.

When to Seek Urgent Help

See a doctor immediately if you have:

• Bloody diarrhea, especially after travel to developing countries
• Severe tummy pain, especially on the right side under your ribs
• High fever with abdominal pain
• Signs of dehydration (dizziness, not urinating, very dry mouth)
• Chest pain or difficulty breathing (could mean liver abscess has spread)

Can You Prevent It?

If traveling to high-risk areas (Asia, Africa, Central/South America):

• Drink safe water: Bottled water or boiled water only (avoid ice cubes)
• Avoid risky foods: No raw vegetables, salads, or street food unless cooked and served hot
• Peel fruits yourself: Only eat fruits you can peel (bananas, oranges)
• Wash hands: Use soap and water, especially before eating and after using the toilet

There is no vaccine to prevent amoebiasis.

Key Takeaways

• Amoebiasis is a parasitic infection from contaminated water/food, common in travelers to developing countries.
• Symptoms: Bloody diarrhea (intestinal) or liver pain + fever (liver abscess).
• Treatment: TWO antibiotics required (tissue + luminal agents) — must complete both.
• With treatment: Excellent outcomes; fever and symptoms resolve within days.
• Prevention: Drink safe water, avoid raw foods, wash hands when traveling.

---

14. References

Primary Literature

1. Stanley SL Jr. Amoebiasis. Lancet 2003;361(9362):1025-34. doi:10.1016/S0140-6736(03)12830-9 [PMID: 12660071]

2. Haque R, Huston CD, Hughes M, et al. Amebiasis. N Engl J Med 2003;348(16):1565-73. doi:10.1056/NEJMra022710 [PMID: 12700377]

3. Petri WA Jr, Haque R, Mann BJ. The bittersweet interface of parasite and host: lectin-carbohydrate interactions during human invasion by the parasite Entamoeba histolytica. Annu Rev Microbiol 2002;56:39-64. [PMID: 12142490]

4. Fu CJ, Zhong JM, Chen WJ, et al. Global burden and trends of the Entamoeba infection-associated diseases from 1990 to 2019: An observational trend study. Acta Trop 2023;238:106801. doi:10.1016/j.actatropica.2022.106801 [PMID: 36801451]

5. Blessmann J, Buss H, Nu PA, et al. Real-time PCR for detection and differentiation of Entamoeba histolytica and Entamoeba dispar in fecal samples. J Clin Microbiol 2002;40(12):4413-7. doi:10.1128/JCM.40.12.4413-4417.2002 [PMID: 12454130]

6. Gonzales MLM, Dans LF, Martinez EG. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev 2009;(2):CD006085. doi:10.1002/14651858.CD006085.pub2

7. Lodhi S, Sarwari AR, Muzammil M, et al. Features distinguishing amoebic from pyogenic liver abscess: a review of 577 adult cases. Trop Med Int Health 2004;9(6):718-23. doi:10.1111/j.1365-3156.2004.01246.x [PMID: 15189460]

8. Choudhuri G, Rangan M, Sharma MP. Amoebic liver abscess: male predominance — fact or fiction? Trop Gastroenterol 1992;13(4):122-6.

9. Ibarra-Perez C. Thoracic complications of amebic abscess of the liver: report of 501 cases. Chest 1981;79(6):672-7. doi:10.1378/chest.79.6.672 [PMID: 7226933]

10. Sharma MP, Ahuja V. Amoebic liver abscess. J Indian Acad Clin Med 2003;4(2):107-11.

11. Gao Y, Yu X, Wang Z, et al. A retrospective case series of amebic colitis clinical features at a tertiary hospital in Beijing from 2021 to 2024. BMC Infect Dis 2025;25(1):15. doi:10.1186/s12879-024-10357-9 [PMID: 41204402]

12. Newman KL, Newman LS, Cannon KS, et al. Sexually transmitted enteric infections in men who have sex with men. Clin Microbiol Rev 2025. doi:10.1128/cmr.00135-24 [PMID: 40960298]

13. Stanley SL Jr. The Entamoeba histolytica cysteine proteinases: structure, function, and pathogenesis. Arch Med Res 2006;37(2):222-3. doi:10.1016/j.arcmed.2005.09.016

14. Costa DM, Gomes MA. Entamoeba histolytica: Plasma membrane components and virulence factors in the invasive process. Curr Top Membr 2025;95:105-135. doi:10.1016/bs.ctm.2024.11.008 [PMID: 40774757]

15. Petri WA Jr, Haque R. Entamoeba histolytica brain abscess. Handb Clin Neurol 2013;114:147-52. doi:10.1016/B978-0-444-53490-3.00009-1 [PMID: 23829905]

16. Tanyuksel M, Petri WA Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev 2003;16(4):713-29. doi:10.1128/CMR.16.4.713-729.2003 [PMID: 14557296]

Guidelines and Resources

17. Centers for Disease Control and Prevention. Amebiasis — Parasites. Available at: https://www.cdc.gov/parasites/amebiasis/

18. World Health Organization. Prevention and Control of Intestinal Parasitic Infections. WHO Technical Report Series No. 749. Geneva: WHO, 1987.

19. World Health Organization. Guidelines for Drinking-water Quality: Fourth Edition Incorporating the First and Second Addenda. Geneva: WHO, 2022.

Additional Key References

20. Oliveira FM, Neumann E, Gomes MA, et al. Entamoeba dispar: could it be pathogenic? Trop Parasitol 2015;5(1):9-14. doi:10.4103/2229-5070.149887

21. Ximénez C, Morán P, Rojas L, et al. Reassessment of the epidemiology of amebiasis: state of the art. Infect Genet Evol 2009;9(6):1023-32. doi:10.1016/j.meegid.2009.06.008

22. Fotedar R, Stark D, Beebe N, et al. Laboratory diagnostic techniques for Entamoeba species. Clin Microbiol Rev 2007;20(3):511-32. doi:10.1128/CMR.00004-07

---

Last Reviewed: 2026-01-09 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances and current local guidelines. Always consult appropriate specialists and refer to the most recent evidence-based guidelines for patient management.